Skip to main content

Nanotech injections successfully restore vision in blind rats

An international team of scientists have restored the vision in blind rats using a nanoparticle-based artificial retina prosthesis that can be injected directly into the eye. The scientific advance has been successfully demonstrated for a period of eight months without the need for surgery. While it is still early days for the research, it suggests it might one day be possible to use the conjugated polymer nanoparticle (P3HT-NP) treatment in humans to correct eye problems –ranging from hereditary retinal dystrophies to the incredibly common age-related macular degeneration.

“In our ‘liquid retina device,’ P3HT nanoparticles spread out over the entire subretinal space and promoted light-dependent activation of spared inner retinal neurons, recovering subcortical, cortical and behavioral visual responses,” Fabio Benfenati, research director at the Italian Institute of Technology, told Digital Trends. “We think that P3HT-NPs provide a new avenue in retinal prosthetics.”

Retinal prostheses refer to implantable devices that are designed to help restore sight in patients with retinal degeneration. They work by introducing visual information into the retina through the electrical stimulation of surviving retinal neurons. While promising, current retinal prostheses have so far been shown to only return low-resolution vision: Useful for things like distinguishing between light and dark or recognizing simple shapes and objects. This new nanotech approach appears far more promising, offering significantly higher resolution. After just one injection, activity in the rats’ visual cortex and visual acuity were the same as those found in healthy rats.

As noted, there is still far more research that needs to be carried out before this approach is tried in humans. But Benfenati suggested that this is part of the road map forward.

“The most obvious development is to approach the first-in-human application with the current technology that will provide the most complete answers,” he said. “This will include a step in larger animals and a long-term study of the nanoparticle fate. I foresee that it will require a few years to be accomplished.”

A paper describing the work, titled “Subretinally injected semiconducting polymer nanoparticles rescue vision in a rat model of retinal dystrophy,” was recently published in the journal Nature Nanotechnology.

Editors' Recommendations

Luke Dormehl
I'm a UK-based tech writer covering Cool Tech at Digital Trends. I've also written for Fast Company, Wired, the Guardian…
Intel’s upcoming iGPU might destroy both Nvidia and Apple M2
A render of Intel's H-series mobile processors.

Intel Meteor Lake might not see the light of day on desktops (not anytime soon, at least), but it seems that the mobile chips are going strong.

According to inside sources, laptops equipped with Meteor Lake chips may not even need a discrete graphics card -- the integrated GPU is going to be powerful enough to rival Nvidia's GTX 1650. That's not all, though. It appears that Intel might even be able to compete against Apple's M2 chip, but in a different way.

Read more
Nvidia may launch 3 new GPUs, and they’re bad news for AMD
An Nvidia GeForce RTX graphics card seen from the side.

In a surprising twist, Nvidia might be releasing not one, but three graphics cards. They all fall under the same RTX 4060 umbrella, although two of them are RTX 4060 Ti models.

This marks a strong entry into the midrange segment for Nvidia, with one of the cards addressing a significant concern -- low VRAM. Should AMD be worried about losing even more business to Team Green?

Read more
Air New Zealand reveals cost of its comfy sleep pods
Air New Zealand's Skynest sleep pods.

Air New Zealand has finally revealed the approximate cost of booking one of its economy-class sleeper pods on a long-haul flight: $400-$600 New Zealand dollars ($250-$380) -- plus the cost of your seat.

Passengers will only be allowed one pod session per flight, so you’ll have to remain crammed in coach for the rest of the time.

Read more